Disc Medicine (IRON) | Financial Analysis & Statements
Disc Medicine Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-67.0M
Net Income
-60.5M
Balance Sheet Metrics
Total Assets
806.9M
Total Liabilities
67.1M
Shareholders Equity
739.8M
Debt to Equity
0.09
Cash Flow Metrics
Operating Cash Flow
-48.5M
Free Cash Flow
-43.3M
Revenue & Profitability Trend
Disc Medicine Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 170.6M | 96.7M | 69.3M | 33.4M | 25.2M |
| Selling, General & Administrative | 65.4M | 33.0M | 21.9M | 14.0M | 5.8M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 236.0M | 129.7M | 91.1M | 47.5M | 30.9M |
| Operating Income | -236.0M | -129.7M | -91.1M | -47.5M | -30.9M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 27.8M | 21.3M | 14.8M | 709.0K | 14.0K |
| Interest Expense | 3.6M | 572.0K | - | - | 2.2M |
| Other Non-Operating Income | 45.0K | -2.0K | -2.0K | -61.0K | -5.0M |
| Pre-tax Income | -211.8M | -109.0M | -76.3M | -46.8M | -36.0M |
| Income Tax | 361.0K | 355.0K | 99.0K | 0 | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -212.2M | -109.4M | -76.4M | -46.8M | -36.0M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -207.9M | -108.3M | -91.0M | -47.3M | -25.9M |
| EPS (Basic) | - | $-3.96 | $-3.42 | $-45.05 | $-44.90 |
| EPS (Diluted) | - | $-3.96 | $-3.42 | $-45.05 | $-44.90 |
| Basic Shares Outstanding | - | 27606022 | 22315877 | 1039490 | 801467 |
| Diluted Shares Outstanding | - | 27606022 | 22315877 | 1039490 | 801467 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Disc Medicine Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 91.1M | 192.4M | 360.4M | 194.6M | 88.0M |
| Short-term Investments | 700.0M | 297.4M | - | - | - |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 12.7M | 3.7M | 5.3M | 3.9M | 2.4M |
| Total Current Assets | 803.9M | 493.6M | 365.7M | 198.5M | 90.5M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 2.3M | 1.6M | 1.9M | 1.4M | 1.6M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 726.0K | 838.0K | 234.0K | 116.0K | 180.0K |
| Total Non-Current Assets | 3.0M | 3.2M | 2.3M | 1.7M | 1.9M |
| Total Assets | 806.9M | 496.8M | 368.0M | 200.2M | 92.4M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 9.0M | 7.9M | 12.6M | 16.2M | 2.6M |
| Short-term Debt | 611.0K | 130.0K | 665.0K | 307.0K | 319.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | 6.4M |
| Total Current Liabilities | 36.6M | 23.3M | 21.4M | 22.6M | 13.4M |
| Non-Current Liabilities | |||||
| Long-term Debt | 30.4M | 29.9M | 1.4M | 1.0M | 1.3M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | 358.0K |
| Total Non-Current Liabilities | 30.4M | 29.9M | 1.4M | 1.0M | 143.2M |
| Total Liabilities | 67.1M | 53.2M | 22.9M | 23.6M | 156.6M |
| Equity | |||||
| Common Stock | 4.0K | 3.0K | 2.0K | 2.0K | 0 |
| Retained Earnings | -510.2M | -298.0M | -188.6M | -112.2M | -65.4M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 739.8M | 443.6M | 345.1M | 176.6M | -64.2M |
| Key Metrics | |||||
| Total Debt | 31.0M | 30.0M | 2.1M | 1.3M | 1.7M |
| Working Capital | 767.3M | 470.3M | 344.2M | 175.9M | 77.1M |
Balance Sheet Composition
Disc Medicine Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -212.2M | -109.4M | -76.4M | -46.8M | -36.0M |
| Depreciation & Amortization | 281.0K | 156.0K | 100.0K | 89.0K | 32.0K |
| Stock-Based Compensation | 34.3M | 16.8M | 5.5M | 2.1M | 507.0K |
| Working Capital Changes | 1.3M | -5.2M | -3.8M | 271.0K | 2.5M |
| Operating Cash Flow | -174.1M | -97.0M | -74.3M | -44.2M | -31.4M |
| Investing Activities | |||||
| Capital Expenditures | -933.0K | -505.0K | -89.0K | -151.0K | -68.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -849.6M | -386.6M | - | - | - |
| Investment Sales | 456.2M | 94.8M | - | - | - |
| Investing Cash Flow | -394.3M | -292.3M | -89.0K | -151.0K | -68.0K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 29.0M | - | - | 0 |
| Debt Repayment | - | - | - | - | -4.6M |
| Financing Cash Flow | 450.1M | 214.9M | 199.1M | 148.8M | 281.2M |
| Free Cash Flow | -181.3M | -94.4M | -73.6M | -42.4M | -27.6M |
| Net Change in Cash | -118.3M | -174.5M | 124.7M | 104.4M | 249.7M |
Cash Flow Trend
Disc Medicine Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
4.99
Forward P/E
-9.09
Price to Book
3.50
PEG Ratio
-9.09
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-35.86%
Return on Assets
-22.55%
Financial Health
Current Ratio
21.94
Debt to Equity
4.19
Beta
2.54
Per Share Data
EPS (TTM)
$-6.01
Book Value per Share
$19.53
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| IRON | 2.6B | 4.99 | 3.50 | -35.86% | 0.00% | 4.19 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






